History

A list of downloadable documents created during development.

Appeal

Background information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination 2

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation 2

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Equality impact assessment - Guidance development

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): assessment report for consultation

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final scope

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final matrix

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on draft scope

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on provisional matrix

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): draft scope for the appraisal

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): provisional matrix of consultees and commentators for the appraisal